According to Zacks, “Actinium Pharmaceuticals, Inc. is a biopharmaceutical company. It specializes in the development of cancer drugs. The company’s principal product candidates under different developmental stages include Actimab-A for the treatment of acute myeloid leukemia in elderly patients and Iomab-B used to condition the bone marrow of patients. Actinium Pharmaceuticals, Inc. is based in New York. “
ATNM has been the subject of a number of other reports. Roth Capital assumed coverage on shares of Actinium Pharmaceuticals in a research note on Thursday, August 25th. They issued a buy rating and a $5.00 target price for the company. FBR & Co set a $9.00 target price on shares of Actinium Pharmaceuticals and gave the company a buy rating in a research note on Thursday, July 21st.
Actinium Pharmaceuticals (NYSEMKT:ATNM) opened at 1.17 on Tuesday. The firm’s 50-day moving average is $1.58 and its 200 day moving average is $1.75. Actinium Pharmaceuticals has a one year low of $1.08 and a one year high of $3.50. The firm’s market capitalization is $55.83 million.
In other news, major shareholder Sloan-Kettering Cance Memorial sold 50,000 shares of the business’s stock in a transaction on Monday, August 29th. The shares were sold at an average price of $1.71, for a total value of $85,500.00. Following the completion of the sale, the insider now directly owns 4,939,490 shares in the company, valued at $8,446,527.90. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.
Institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. boosted its position in Actinium Pharmaceuticals by 19.2% in the second quarter. Vanguard Group Inc. now owns 1,581,228 shares of the company’s stock valued at $2,798,000 after buying an additional 254,318 shares during the last quarter. GSA Capital Partners LLP acquired a new stake in shares of Actinium Pharmaceuticals during the second quarter valued at about $247,000. BlackRock Institutional Trust Company N.A. raised its stake in shares of Actinium Pharmaceuticals by 11.3% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 462,683 shares of the company’s stock valued at $819,000 after buying an additional 47,131 shares during the period. Finally, BlackRock Fund Advisors raised its stake in shares of Actinium Pharmaceuticals by 31.5% in the second quarter. BlackRock Fund Advisors now owns 102,003 shares of the company’s stock valued at $181,000 after buying an additional 24,453 shares during the period.
Actinium Pharmaceuticals Company Profile
Actinium Pharmaceuticals, Inc (Actinium) is a clinical-stage biopharmaceutical company engaged in developing cancer treatments. The Company is engaged in developing therapies for diseases using its alpha particle immunotherapy platform and other related technologies. The Company’s products include Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), and Iomab-B, an antibody-drug construct containing iodine 131 (I-131).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Actinium Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actinium Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.